November 3, 2025
In this article from The DrugTarget Review, Pheast’s Chief Medical Officer, Raphaël Rousseau, highlightsgrowing industry momentum behind macrophage checkpoint inhibition as anext-generation immuno-oncology strategy, and shifted attention toward CD24.Dr. Rousseau outlines how targeting the CD24 “don’t eat me” signal can restoremacrophage-mediated tumor clearance and address gaps in T cell–focusedtherapies, especially in immune-excluded solid tumors. The piece also exploresthe emerging clinical and strategic landscape, illustrating howmacrophage-directed therapies such as PHST001 may offer broad potential forcombination therapies across solid tumor settings.